Mode
Text Size
Log in / Sign up

PDA closure rates decrease significantly after second and third courses of cyclooxygenase inhibitors in preterm infantsRepeated drug courses show lower closure rates for heart defects

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that PDA closure rates significantly decrease after the second and third courses of cyclooxygenase inhibitors.

This meta-analysis of 33 studies evaluates the efficacy of cyclooxygenase inhibitors, including ibuprofen and indomethacin, for the management of Patent Ductus Arteriosus (PDA) in preterm infants. The analysis specifically compares the closure rates achieved after first, second, and third courses of these medications.

The primary finding is that PDA closure rates decrease with subsequent courses. The closure rate after the first course was 62% (95% CI 57-67%). This rate dropped to 46% (95% CI 40-52%; p < 0.001) after a second course and further declined to 38% (95% CI 27-51%; p = 0.001) after a third course.

A significant limitation noted by the authors is that data on adverse events were limited, which prevented a formal meta-analysis of the safety of repeated courses. Clinical application is tempered by this lack of robust safety data for repeated interventions. The findings suggest that while repeated courses are used, the probability of successful closure diminishes with each subsequent course.

How this fits prior evidence

This meta-analysis addresses a gap in the management of Patent Ductus Arteriosus (PDA) in preterm infants by evaluating the impact of repeated cyclooxygenase inhibitor courses. It provides specific data on the declining success rates of subsequent treatments. This finding complements the existing evidence that transcatheter PDA closure improves safety and reduces radiation compared to fluoroscopy, though the current study focuses on pharmacological management and its diminishing efficacy over repeated courses.

When a baby is born prematurely, they may have a heart condition called Patent Ductus Arteriosus. This is a small opening in a blood vessel that should have closed before birth. Doctors often use medications called cyclooxygenase inhibitors, such as ibuprofen or indomethacin, to help close this opening.

Researchers looked at 33 different studies to see how well these drugs worked over time. They found that the first course of medication had a 62% success rate in closing the opening. However, the success rate dropped to 46% after a second course and even lower to 38% after a third course.

While these results show a clear drop in effectiveness for later treatments, there is a catch. The researchers had limited data on side effects and safety for these repeated doses. Because of this missing information, the safety of using multiple rounds of medication is not yet fully clear.

What this means for you:
Success rates for closing a specific heart opening in preterm infants drop after the first round of medication.

Common questions

What are the success rates for the first course of medication?

The first course of cyclooxygenase inhibitors, which include medications like ibuprofen and indomethacin, had a 62% success rate in closing the heart opening in preterm infants.

Do subsequent rounds of medication work as well?

No, the data shows that success rates drop after repeated treatments. The closure rate was 46% after a second course and 38% after a third course, which were both significantly lower than the first course.

Is it safe to give these medications multiple times?

The data on safety and side effects for repeated courses of these medications is currently limited. Because of this lack of information, the safety of multiple rounds cannot be fully determined from this data.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Background: Cyclooxygenase (COX) inhibitors have been used to treat hemodynamically significant patent ductus arteriosus (PDA) in preterm infants. If the PDA remains hemodynamically significant after an initial course, additional courses of COX inhibitors or surgical intervention are considered. This systematic review evaluates PDA closure rates and safety after repeated courses of COX inhibitors in preterm infants. Methods: Embase, Medline, and two other databases were searched through April 2026 (pre-registered in PROSPERO [CRD42023454003]). Studies reporting PDA closure rates after two or more courses of COX inhibitors were included. Risk of bias was assessed using Joanna Briggs Institute tools. Meta-analyses with random-effects models were performed to calculate the proportions of PDA closure. Multilevel mixed-effects meta-regression was used to compare closure rates across treatment courses while accounting for within-study correlations. Results: A total of 33 studies were included. The PDA closure rates after the first, second, and third courses of COX inhibitors were 62% (95% confidence interval [CI] 57-67%), 46% (95% CI 40-52%; p < 0.001 vs the first course), and 38% (95% CI 27-51%; p = 0.001 vs the first course), respectively. Lower closure rates with repeated courses were also observed across most subgroups (extremely preterm/extremely low birth weight, ibuprofen, indomethacin, and intravenous administration), except for the second course of oral administration. Data on adverse events were limited, preventing meta-analysis. Conclusions: PDA closure rates after the second and third courses of COX inhibitors were lower than those after the first course in preterm infants. Evidence regarding the safety of repeated courses remains limited.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.